Examining cannabis use among Black and White cancer patients
Cannabis Use and Outcomes in Black and White Patients With Cancer
State University of New York at Buffalo · NCT06037681
This study looks at how Black and White cancer patients use cannabis, opioids, and tobacco to manage their pain and symptoms over a year.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 600 (estimated) |
| Ages | 21 Years to 99 Years |
| Sex | All |
| Sponsor | State University of New York at Buffalo (other) |
| Locations | 3 sites (Buffalo, New York and 2 other locations) |
| Trial ID | NCT06037681 on ClinicalTrials.gov |
What this trial studies
This observational study aims to understand how Black and White patients with solid tumor cancer utilize cannabis, opioids, and tobacco. Researchers will employ a momentary ecological assessment via a smartphone app to gather real-time data on patient-reported pain and symptom management over a 12-month period. The study will enroll 200 participants, split evenly between cannabis users and non-users, to assess the longitudinal impact of cannabis on opioid use and pain management. Data will be collected remotely to minimize participant burden and enhance engagement.
Who should consider this trial
Good fit: Ideal candidates are Black or White adults aged 21 and older with solid tumor cancer diagnosed within the last three years who experience pain and have been prescribed opioids.
Not a fit: Patients with lymphoma, leukemia, melanoma, or those using CBD only or synthetic cannabis in the past three months may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide valuable insights into effective pain management strategies for cancer patients, particularly in underrepresented populations.
How similar studies have performed: While studies on cannabis use in cancer patients exist, this specific approach using momentary ecological assessment is relatively novel and has not been extensively tested.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * 21 years or older * Black or white race * Solid tumor cancer within 3 years of enrollment * Cannabis use of at least once a week or non cannabis use for 3 months * experience pain but spend less than 50% in bed or chair * Prescribed or take opioid for at least 30 days for pain * Not pregnant or planning to become pregnant in the next 12 months * English speaking Exclusion Criteria: * Lymphoma, leukemia, and melanoma * CBD only use * Synthetic cannabis use in past 3 months = Prescribed Medically-prescribed synthetic cannabis (e.g., dronabinol \[Marinol, Syndros\], Epidiolex) * race other than Black or White
Where this trial is running
Buffalo, New York and 2 other locations
- University at Buffalo — Buffalo, New York, United States (RECRUITING)
- Thomas Jefferson University — Philadelphia, Pennsylvania, United States (RECRUITING)
- University of Pennsylvania — Philadelphia, Pennsylvania, United States (RECRUITING)
Study contacts
- Principal investigator: Salimah Meghani, PhD — University of Pennsylvania
- Study coordinator: Colleen Kilanowski, MS
- Email: ckk@buffalo.edu
- Phone: 716-829-5977
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Cancer, Solid tumor, opioids, cannabis